Display options
Cite
Beitler JJ, Wadler S, Haynes H, et al. Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. Med Oncol. 1995;12(2):115-20doi: 10.1007/BF01676712.
Beitler, J. J., Wadler, S., Haynes, H., Fell, S., Rozenblit, A., Wolf, E., & Levine, B. A. (1995). Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. Medical oncology (Northwood, London, England), 12(2), 115-20. https://doi.org/10.1007/BF01676712
Beitler, J J, et al. "Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer." Medical oncology (Northwood, London, England) vol. 12,2 (1995): 115-20. doi: https://doi.org/10.1007/BF01676712
Beitler JJ, Wadler S, Haynes H, Fell S, Rozenblit A, Wolf E, Levine BA. Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. Med Oncol. 1995 Jun;12(2):115-20. doi: 10.1007/BF01676712. PMID: 8535661.
Copy Download .nbib Format: NLM
Share it on

Med Oncol. 1995 Jun;12(2):115-20. doi: 10.1007/BF01676712.

Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.

Medical oncology (Northwood, London, England)

J J Beitler, S Wadler, H Haynes, S Fell, A Rozenblit, E Wolf, B A Levine

Affiliations

  1. Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, USA.

PMID: 8535661 DOI: 10.1007/BF01676712

Abstract

A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 micrograms kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.

References

  1. Cancer. 1993 Mar 1;71(5):1726-30 - PubMed
  2. Br J Radiol. 1978 Jul;51(607):515-23 - PubMed
  3. Radiology. 1977 Jan;122(1):239-42 - PubMed
  4. Semin Oncol. 1994 Aug;21(4):474-82 - PubMed
  5. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):587-91 - PubMed
  6. Int J Radiat Oncol Biol Phys. 1987 Aug;13(8):1161-6 - PubMed
  7. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1133-5 - PubMed
  8. Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1373-83 - PubMed
  9. Br J Surg. 1980 Jun;67(6):381-90 - PubMed
  10. Radiother Oncol. 1989 Sep;16(1):65-72 - PubMed
  11. J Clin Oncol. 1992 Feb;10 (2):269-74 - PubMed
  12. Radiother Oncol. 1992 Dec;25(4):287-94 - PubMed
  13. Radiother Oncol. 1991 Jan;20(1):3-9 - PubMed
  14. N Engl J Med. 1992 Jun 11;326(24):1593-8 - PubMed
  15. Cancer Res. 1990 Sep 15;50(18):5735-9 - PubMed
  16. Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):675-8 - PubMed
  17. Br J Surg. 1980 Jul;67(7):457-61 - PubMed
  18. Radiother Oncol. 1991 Jan;20(1):1-2 - PubMed
  19. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):935-40 - PubMed
  20. Int J Radiat Oncol Biol Phys. 1992;24(2):235-40 - PubMed
  21. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):3-8 - PubMed

Substances

MeSH terms

Publication Types

Grant support